Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2008

View Archived Issues

Ranbaxy patents novel muscarinic receptor antagonists

New analgesic agents imparted in recent patent literature

Novel treatments for dermatological disorders disclosed in recent patents

Sanofi pasteur's acquisition of Acambis completed

Manageable levels of neuropathy in breast cancer patients receiving eribulin

Novel GIP antagonist shows efficacy in preclinical models of obesity and type 2 diabetes

Positive phase I interim results of XOMA-052 in type 2 diabetes

Almirall receives payment from Forest as part of aclidinium collaboration

Arana Therapeutics provides update on recent pipeline activity

Safety results presented at the WSC from the V-10153 stroke thrombolysis trial

LAU-0901 neuroprotective in a rat model of focal cerebral ischemia

BioMS receives milestone payment based on positive review of MAESTRO-01 trial

MAP completes enrollment in phase III nebulized budesonide trial in children with asthma

ChemBridge enters into new discovery alliance with AstraZeneca

Discovery Laboratories completes response to FDA approvable letter for Surfaxin

BIO-11006 shows promise as a COPD treatment

Dyax completes BLA for DX-88 in hereditary angioedema

Inspire requests SPA process for Prolacria for dry eye

Independent Data Safety Monitoring supports continuation of Iluvien trial

Cellerant Therapeutics receives contract for acute radiation syndrome treatment

CHMP issues positive opinion for olanzapine long-acting injection in schizophrenia

Concert commences phase I CTP-347 trial in healthy volunteers

FDA approves Nasacort AQ Nasal Spray for children with allergic rhinitis

ImClone starts enrollment in phase II IMC-A12 trial in advanced breast cancer

RegeneRx enrolls first subject in phase Ib RGN-352 trial

Xenome evaluates XEN-2174 in phase II trial in acute pain

Thallion enrolls first patient in phase II TLN-4601 trial; FDA approves trial in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...